Health And Fertility In World Health Organization Group 2 Anovulatory Women

    May 2012 in “ Human Reproduction Update
    D. T. Baird, Adam Balen, Héctor F. Escobar-Morreale, Johannes L.H. Evers, Bart C.J.M. Fauser, Paul W. Franks, Anna Glasier, Roy Homburg, Carlo La Vecchia, Pier Giorgio Crosignani, Paul Devroey, K. Diedrich, Lynn R. Fraser, Luca Gianaroli, Ingeborg Liebaers, Arne Sunde, Juha S. Tapanainen, Basil C. Tarlatzis, A. Van Steirteghem, Anna Veiga
    Image of study
    TLDR Women with PCOS may take longer to get pregnant but can have a normal family size, and should manage their overall health to reduce long-term health risks.
    The document from May 19, 2012, reviews health and fertility issues in WHO group 2 anovulatory women, with a focus on those with polycystic ovary syndrome (PCOS). It finds that PCOS, a common cause of infertility, has a multifactorial etiology with genetic predisposition. Women with PCOS may have increased time to pregnancy but not necessarily reduced family size or higher miscarriage rates. Clomiphene citrate is the first-line treatment for anovulatory infertility in PCOS, followed by gonadotrophins and laparoscopic ovarian surgery, with aromatase inhibitors like letrozole also showing promise. The document stresses the importance of monitoring general health in these patients due to long-term metabolic and cardiovascular risks, advocating for early prevention and healthy lifestyle changes. It also notes that modest weight loss can restore fecundity in overweight PCOS patients. Specific prevalence rates of skin conditions in Turkish women with PCOS are provided, and the document discusses the risks of multiple pregnancies and long-term health issues like endometrial cancer and Type 2 diabetes associated with PCOS. The need for careful ovulation induction and vigilance for long-term health risks is emphasized.
    Discuss this study in the Community →

    Research cited in this study

    8 / 8 results

    Related Community Posts Join

    6 / 12 results

      community How does hair loss and recovery work?

      in Chat  12 upvotes 3 months ago
      Hair loss varies due to genetic sensitivity to DHT and other factors. Treatments discussed include finasteride, minoxidil, RU58841, and microneedling.

      community C’est terrible - at my wits end

      in Female  449 upvotes 1 year ago
      A 29-year-old woman is experiencing gradual hair thinning since age 15, suspects Androgenic Alopecia, and has tried 5% minoxidil with little success. She has purchased various hair loss treatments including minoxidil, dutasteride, finasteride, and spironolactone, but is cautious about starting them due to potential interactions with her ADHD medication.

      community Female, 30, PCOS diagnosis, MPB Norwood 2. Endo refuses to give anything other than Spironolactone. Feel like I’m at my wit’s end here.

      in Female  53 upvotes 1 year ago
      A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

      community Why balding gets worse in every generation?

      in Chat  81 upvotes 6 months ago
      Balding seems to worsen with each generation, possibly due to stress, diet, and environmental factors. The user started treatments like Minoxidil and finasteride.

    Related Research

    1 / 1 results